Logo image of NUVB

NUVATION BIO INC (NUVB) Stock Fundamental Analysis

USA - NYSE:NUVB - US67080N1019 - Common Stock

7.17 USD
+0.02 (+0.28%)
Last: 11/20/2025, 9:45:09 AM
Fundamental Rating

2

Taking everything into account, NUVB scores 2 out of 10 in our fundamental rating. NUVB was compared to 192 industry peers in the Pharmaceuticals industry. NUVB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, NUVB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NUVB has reported negative net income.
NUVB had a negative operating cash flow in the past year.
In the past 5 years NUVB always reported negative net income.
NUVB had a negative operating cash flow in each of the past 5 years.
NUVB Yearly Net Income VS EBIT VS OCF VS FCFNUVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

NUVB's Return On Assets of -36.15% is in line compared to the rest of the industry. NUVB outperforms 45.83% of its industry peers.
With a Return On Equity value of -66.74%, NUVB perfoms like the industry average, outperforming 47.92% of the companies in the same industry.
Industry RankSector Rank
ROA -36.15%
ROE -66.74%
ROIC N/A
ROA(3y)-44.25%
ROA(5y)-34.58%
ROE(3y)-50.3%
ROE(5y)-38.48%
ROIC(3y)N/A
ROIC(5y)N/A
NUVB Yearly ROA, ROE, ROICNUVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

NUVB has a better Gross Margin (54.26%) than 64.58% of its industry peers.
NUVB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NUVB Yearly Profit, Operating, Gross MarginsNUVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

4

2. Health

2.1 Basic Checks

NUVB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NUVB has been increased compared to 1 year ago.
Compared to 5 years ago, NUVB has more shares outstanding
NUVB has a worse debt/assets ratio than last year.
NUVB Yearly Shares OutstandingNUVB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
NUVB Yearly Total Debt VS Total AssetsNUVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 2.61 indicates that NUVB is not a great score, but indicates only limited risk for bankruptcy at the moment.
NUVB has a Altman-Z score of 2.61. This is in the better half of the industry: NUVB outperforms 67.71% of its industry peers.
A Debt/Equity ratio of 0.61 indicates that NUVB is somewhat dependend on debt financing.
NUVB has a worse Debt to Equity ratio (0.61) than 66.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Altman-Z 2.61
ROIC/WACCN/A
WACC8.82%
NUVB Yearly LT Debt VS Equity VS FCFNUVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 8.48 indicates that NUVB has no problem at all paying its short term obligations.
NUVB's Current ratio of 8.48 is fine compared to the rest of the industry. NUVB outperforms 77.08% of its industry peers.
A Quick Ratio of 8.39 indicates that NUVB has no problem at all paying its short term obligations.
NUVB's Quick ratio of 8.39 is fine compared to the rest of the industry. NUVB outperforms 78.13% of its industry peers.
Industry RankSector Rank
Current Ratio 8.48
Quick Ratio 8.39
NUVB Yearly Current Assets VS Current LiabilitesNUVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for NUVB have decreased strongly by -48.84% in the last year.
NUVB shows a strong growth in Revenue. In the last year, the Revenue has grown by 1137.19%.
EPS 1Y (TTM)-48.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
Revenue 1Y (TTM)1137.19%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1704.68%

3.2 Future

NUVB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.75% yearly.
The Revenue is expected to grow by 207.92% on average over the next years. This is a very strong growth
EPS Next Y-28.16%
EPS Next 2Y-4.84%
EPS Next 3Y3.77%
EPS Next 5Y53.75%
Revenue Next Year1263.17%
Revenue Next 2Y675.33%
Revenue Next 3Y382.62%
Revenue Next 5Y207.92%

3.3 Evolution

NUVB Yearly Revenue VS EstimatesNUVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
NUVB Yearly EPS VS EstimatesNUVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NUVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUVB Price Earnings VS Forward Price EarningsNUVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUVB Per share dataNUVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.84%
EPS Next 3Y3.77%

More info and screens

0

5. Dividend

5.1 Amount

NUVB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVATION BIO INC

NYSE:NUVB (11/20/2025, 9:45:09 AM)

7.17

+0.02 (+0.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)03-04 2026-03-04/amc
Inst Owners66.73%
Inst Owner Change-2.97%
Ins Owners17.9%
Ins Owner Change0.57%
Market Cap2.46B
Revenue(TTM)26.75M
Net Income(TTM)-217.48M
Analysts84.29
Price Target8.89 (23.99%)
Short Float %24.48%
Short Ratio8.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.93%
Min EPS beat(2)0.88%
Max EPS beat(2)6.98%
EPS beat(4)3
Avg EPS beat(4)0.55%
Min EPS beat(4)-6.56%
Max EPS beat(4)6.98%
EPS beat(8)5
Avg EPS beat(8)-11.26%
EPS beat(12)9
Avg EPS beat(12)-2.73%
EPS beat(16)12
Avg EPS beat(16)-0.14%
Revenue beat(2)2
Avg Revenue beat(2)660.6%
Min Revenue beat(2)94.49%
Max Revenue beat(2)1226.72%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.02%
PT rev (3m)21.59%
EPS NQ rev (1m)33.67%
EPS NQ rev (3m)33.98%
EPS NY rev (1m)-0.81%
EPS NY rev (3m)1.7%
Revenue NQ rev (1m)92.53%
Revenue NQ rev (3m)176.43%
Revenue NY rev (1m)-2.04%
Revenue NY rev (3m)92.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 92.02
P/FCF N/A
P/OCF N/A
P/B 7.55
P/tB 7.83
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.08
BVpS0.95
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.15%
ROE -66.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.26%
FCFM N/A
ROA(3y)-44.25%
ROA(5y)-34.58%
ROE(3y)-50.3%
ROE(5y)-38.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 581.54%
Cap/Sales 30.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.48
Quick Ratio 8.39
Altman-Z 2.61
F-Score4
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)79.93%
Cap/Depr(5y)109.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
EPS Next Y-28.16%
EPS Next 2Y-4.84%
EPS Next 3Y3.77%
EPS Next 5Y53.75%
Revenue 1Y (TTM)1137.19%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1704.68%
Revenue Next Year1263.17%
Revenue Next 2Y675.33%
Revenue Next 3Y382.62%
Revenue Next 5Y207.92%
EBIT growth 1Y-73.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-186.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-174.8%
OCF growth 3YN/A
OCF growth 5YN/A

NUVATION BIO INC / NUVB FAQ

What is the ChartMill fundamental rating of NUVATION BIO INC (NUVB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NUVB.


What is the valuation status for NUVB stock?

ChartMill assigns a valuation rating of 0 / 10 to NUVATION BIO INC (NUVB). This can be considered as Overvalued.


How profitable is NUVATION BIO INC (NUVB) stock?

NUVATION BIO INC (NUVB) has a profitability rating of 1 / 10.


What is the expected EPS growth for NUVATION BIO INC (NUVB) stock?

The Earnings per Share (EPS) of NUVATION BIO INC (NUVB) is expected to decline by -28.16% in the next year.